These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 16839270)
61. Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer. Kang DW; Bittner B; Sugarman BJ; Zepeda ML; Printz MA PLoS One; 2021; 16(7):e0254765. PubMed ID: 34292990 [TBL] [Abstract][Full Text] [Related]
62. Viral shedding after p53 adenoviral gene therapy in 10 cases of esophageal cancer. Kawahira H; Matsushita K; Shiratori T; Shimizu T; Nabeya Y; Hayashi H; Ochiai T; Matsubara H; Shimada H Cancer Sci; 2010 Jan; 101(1):289-91. PubMed ID: 20175784 [TBL] [Abstract][Full Text] [Related]
63. Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size. Rohner NA; Thomas SN ACS Biomater Sci Eng; 2017 Feb; 3(2):153-159. PubMed ID: 29888321 [TBL] [Abstract][Full Text] [Related]
64. THE FORMATION OF AGGLUTININS WITHIN LYMPH NODES. McMaster PD; Hudack SS J Exp Med; 1935 May; 61(6):783-805. PubMed ID: 19870391 [TBL] [Abstract][Full Text] [Related]
65. Controlling timing and location in vaccines. Irvine DJ; Aung A; Silva M Adv Drug Deliv Rev; 2020; 158():91-115. PubMed ID: 32598970 [TBL] [Abstract][Full Text] [Related]
66. Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8 Zaric M; Becker PD; Hervouet C; Kalcheva P; Doszpoly A; Blattman N; A O' Neill L; Yus BI; Cocita C; Kwon SY; Baker AH; Lord GM; Klavinskis LS Nat Commun; 2019 May; 10(1):2214. PubMed ID: 31101810 [TBL] [Abstract][Full Text] [Related]
67. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. Snook AE; Baybutt TR; Hyslop T; Waldman SA Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079 [TBL] [Abstract][Full Text] [Related]
68. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Hayes CS; Shicora AC; Keough MP; Snook AE; Burns MR; Gilmour SK Cancer Immunol Res; 2014 Mar; 2(3):274-85. PubMed ID: 24778323 [TBL] [Abstract][Full Text] [Related]
69. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. Diaz CM; Chiappori A; Aurisicchio L; Bagchi A; Clark J; Dubey S; Fridman A; Fabregas JC; Marshall J; Scarselli E; La Monica N; Ciliberto G; Montero AJ J Transl Med; 2013 Mar; 11():62. PubMed ID: 23497415 [TBL] [Abstract][Full Text] [Related]
70. Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice. Zhao Z; Liu W; Su Y; Zhu J; Zheng G; Luo Q; Jin X J Exp Clin Cancer Res; 2010 Jan; 29(1):1. PubMed ID: 20044941 [TBL] [Abstract][Full Text] [Related]
71. A human full-skin culture system for interventional studies. Steinstraesser L; Rittig A; Gevers K; Sorkin M; Hirsch T; Kesting M; Sand M; Al-Benna S; Langer S; Steinau HU; Jacobsen F Eplasty; 2009; 9():e5. PubMed ID: 19198642 [TBL] [Abstract][Full Text] [Related]
72. Polarization of protective immunity induced by replication-incompetent adenovirus expressing glycoproteins of pseudorabies virus. Han YW; Aleyas AG; George JA; Kim SJ; Kim HK; Yoon HA; Yoo DJ; Kang SH; Kim K; Eo SK Exp Mol Med; 2008 Dec; 40(6):583-95. PubMed ID: 19116444 [TBL] [Abstract][Full Text] [Related]
73. Adenoviral vectors for gene therapy. Douglas JT Mol Biotechnol; 2007 May; 36(1):71-80. PubMed ID: 17827541 [TBL] [Abstract][Full Text] [Related]
74. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Plog MS; Guyre CA; Roberts BL; Goldberg M; St George JA; Perricone MA Hum Gene Ther; 2006 Jul; 17(7):705-16. PubMed ID: 16839270 [TBL] [Abstract][Full Text] [Related]
75. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Perricone MA; Claussen KA; Smith KA; Kaplan JM; Piraino S; Shankara S; Roberts BL Mol Ther; 2000 Mar; 1(3):275-84. PubMed ID: 10933943 [TBL] [Abstract][Full Text] [Related]
77. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823 [TBL] [Abstract][Full Text] [Related]
78. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627 [TBL] [Abstract][Full Text] [Related]
79. Effect of administration route on the biodistribution and shedding of replication-deficient HAdV-5: a qualitative modelling approach. Tiesjema B; Hermsen HP; van Eijkeren JC; Brandon EF Curr Gene Ther; 2010 Apr; 10(2):107-27. PubMed ID: 20222861 [TBL] [Abstract][Full Text] [Related]